Drivers, Best Practices and Strategies for Pre-Competitive Consortia June 22-23, 2009 Marriott at Metro Center Hotel Washington, DC
Co-Organized with The Critical Path InstituteFinal Agenda Now Available!* View a PDF of the brochure * Register Today and Save! Early Registration Discount ends this Friday, April 3rd.
As the pharmaceutical industry moves closer to what has been described as a "Revenue Cliff", as a number of key patents expire on major drugs, at the same time as the industry confronts the additional challenges of a dramatic decline in pipeline productivity, declining availability of R&D resources, and increased regulatory and business practice pressures, new models for drug discovery and development become critical to the industry's future. Pre-competitive consortia are becoming an important alternative model for accelerating drug discovery and development, while sharing resources and costs. Current consortia have produced some notable successes and provide a valuable approach for better understanding where the best opportunities for collaboration may exist, what strategies to employ and how to win support for such efforts.
This important program will explore pre-competitive, multiple party, consortia-based collaborations in drug discovery and development, examining key questions and issues, including:
- How should equal partners be brought together?
- What if the partners are not equal in size or contribution?
- What is the impact of creating and communicating a compelling Vision and Mission for such consortia?
- What are the Best Solutions for data contribution and sharing?
- What Organizational Models work most effectively in which situations?
- What are the current Best Practices for how such consortia should be organized and managed?
- What New Models are proven to generate higher levels of IP?
- How can IP be shared effectively, while being protected?
- How to move from Collaborative Consortia back into competitive programs.
This leading-edge conference will feature key speakers from pharmaceutical companies and non-profit organizations, with first-hand experience in setting up and managing successful consortia, as we explore the most important new models, key issues, challenges and best practices of Collaborative Innovation in Biomedicine.
Agenda-at-a-Glance:
SUNDAY, JUNE 21, 2009
PRE-CONFERENCE SHORT COURSE:
The Architecture of Collaborative Innovation
Course Leader: Robert Porter Lynch, Chief Executive Officer, The Warren Company; Chairman Emeritus, The Association of Strategic Alliance Professionals, Inc. (ASAP); Author of 5 Books on Strategic Alliances, including "The Architecture of Trust" (to be published in 2009)
MONDAY, JUNE 22, 2009 - DAY ONE
The Power of Collaborative Innovation and the Architecture of Trust
Robert Porter Lynch
Defining Characteristics of Successful Models of Collaborative Innovation
William Mattes, Ph.D., Director, Toxicology, The Critical Path Institute
Revising the Role of Intellectual Property - From Exclusivity to Partnership
Richard Gold, Ph.D., Professor and Director, Center for Intellectual Property Policy, McGill University
Information Flows and IP Control in Pre-Competitive Collaborations
Mark Anthony Mersereau, Esq., PTC Intellectual Property Law, LLC
"Radical Collaboration" - How IBM Transformed the Semiconductor Industry through Pre-Competitive Collaborative Innovation - A Hi-Tech Industry Case Study
Bernard Meyerson, Ph.D., IBM Fellow and Vice President, Strategic Alliances and Chief Technology Officer, Systems and Technology Group, IBM
How Collaborative Innovation Aids the Regulatory Process and Vice-Versa
Bruno Flamion, MD, Ph.D., Professor of Physiology and Pharmacology, University Of Namur, Belgium,and Chairman, Scientific Advice Working Party, The European Medicines Agency (EMEA)
FACILITATING DATA SHARING
Keynote Address
Speeding Research and Development through a Collaborative Ecosystem
Ken Buetow, Ph.D., Associate Director for Bioinformatics and Information Technology and Director of Center for Biomedical Informatics and Information Technology, National Cancer Institute (NCI); Co-founder, caBIG(TM) and The BIG Health Consortium(TM)
Taking a Pre-Competitive Approach to Defining Standards and Leveraging Best Practices to Enable Basic Research Collaboration
Martin Leach, Ph.D., Executive Director, Basic Research & Biomarker IT, Merck & Co., Inc.
Gaining Efficiencies through Open Innovation
Susie Stephens, Ph.D., Principal Research Scientist, Lilly Research Labs, Eli Lilly and Company
Customer Perspective on Pre-Competitive Software Development (tentative)
The Value of and Standards for Facilitated Data Sharing- Collaborative Activities in Research and Healthcare
Rebecca Kush, Ph.D., Founder, President and CEO, Clinical Data Interchange Standards Consortium (CDISC)
Jessica Nadler, Ph.D., AAAS Fellow for Policy and Technology Policy, Department of Health and Human Services
Jessica Nadler, Ph.D., AAAS Fellow for Policy and Technology Policy, Department of Health and Human Services
Breakout Round-Table Discussions
Issues of Shared IP from Consortia Research
Moderators: Richard Gold, Ph.D., and Mark A. Mersereau, Esq.
Moderators: Richard Gold, Ph.D., and Mark A. Mersereau, Esq.
Solutions for Facilitating Data Sharing in Collaborative Research
Moderator: Martin Leach, Ph.D.
Overcoming Resistance to Sharing Drug Safety Results
Moderator: Arthur Holden
Governance, Organizational Management and Trust Building Issues for Consortia
Moderator: Robert Porter Lynch
Shared Development of Tools and Technology
Moderator: Erik Kuja and Catherine Oyler
Working to Enable Regulatory Changes
Moderator: Bruno Flamion, Ph.D.
Information Infrastructure for Collaborative Therapy Development
Jay "Marty" Tennenbaum, Ph.D.
TUESDAY, JUNE 23, 2009 - DAY TWO
Round-Table Reports
CONSORTIA CASE STUDIES
The Innovative Medicines Initiative: Driving a New Paradigm in Pre-Competitive Research
Jackie Hunter, Ph.D., Senior Vice President, Science Environment Development, GlaxoSmithKline
Successes and Renewal of the Dundee Signaling Consortium
Malcolm M. Skingle, Ph.D., Director, European Academic Liaison, Genetic & Discovery Alliances, GlaxoSmithKline
Where No One Has Gone Before - A Collaborative Model to De-risk Discovery and Development of First-in-Class Therapies (How Non-Profits can use their Mission to be a Unique Convener of Pre-Competitive Collaborations)
Russell "Rusty" Bromley, Chief Operating Officer, Myelin Repair Foundation
Enlight Biosciences and Related Examples: Pre-competitive Collaboration to Ensure Development and Acceptance of Critical New Technology
Erik Kuja, Strategic Alliances, Pfizer Worldwide Business Development
Catherine Oyler, Senior Director, Emerging Technologies, Corporate Office of Science and Technology, Johnson & Johnson
DRUG SAFETY CONSORTIA
The Serious Adverse Event Consortium, Ltd. [SAEC] - Formation and Current Status of an International Effort to Understand the Genetic Basis of Drug Related Serious Adverse Events
Arthur Holden, Chairman and Chief Executive Officer, Serious Adverse Events Consortium; Former Chairman and Chief Executive Officer, Pharmaceutical Biomedical Research Consortium Ltd.; Former Chairman, The SNP Consortium
The Drug Safety Executive Council (DSEC) Efforts in Collaborative Drug Safety Evaluation
Ernie Bush, Ph.D., Vice President and Scientific Director, Preclinical Safety, Cambridge Healthtech Associates
Luncheon Presentation:
Health Commons: An e-Business Approach to Collaborative Therapy Development
Jay "Marty" Tennenbaum, Ph.D., Chairman and Chief Scientist, CollabRx, Inc.
CONSORTIA CASE STUDIES (Continued)
BIOMARKER CONSORTIA
HESI's Experience in Collaborative Approaches to Science
Syril D. Pettit, M.E.M., Associate Director, Scientific Outreach, ILSI Health and Environmental Sciences Institute (HESI)
The Predictive Safety Testing Consortium: Advancing Translational Toxicology through Inter-disciplinary and Inter-organizational Collaboration
Elizabeth Walker, Ph.D., Assistant Director, Toxicology, Predictive Safety Testing Consortium, The Critical Path Institute
The Future of Pre-Competitive Consortia - A Best Practices Panel Discussion
Discussion Leader:
William Mattes, Ph.D., Director, Toxicology, The Critical Path Institute
Panelists:
Jay "Marty" Tennenbaum, Ph.D., Chairman and Chief Scientist, CollabRx, Inc.
Arthur Holden, Chairman and Chief Executive Officer, Serious Adverse Events Consortium
Martin Leach, Ph.D., Executive Director, Basic Research & Biomarker IT, Merck & Co., Inc.
Jackie Hunter, Ph.D., Senior Vice President, Science Environment Development, GlaxoSmithKline
Be part of this leading-edge conference...Register Early and Save up to $350!
Corporate Sponsor:
PTC Intellectual Property Law LLC
For information on sponsorships and exhibits, please contact:
Arnie Wolfson
Manager, Business Development
Phone: 781-972-5431
E-mail: awolfson@healthtech.com
For detailed information on this event and to register, visit: http://www.healthtech.com/cbi
CHI, 250 First Avenue, Suite 300, Needham, Massachusetts 02494
This email communication is for commercial purposes. If it is not of interest to you, please disregard and we apologize for any inconvenience this may have caused.
To prevent further emails, click here or go to www.chicorporate.com/corporate_unsubscribe.aspx
No comments:
Post a Comment